A call for physiopathological ethics

Molecular Therapy

Volumn 16, Issue 11, 2008, Pages 1771-1772

  Lowenstein, Pedro R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AROMATIC CARBOXYLIC ACID; COMPLEMENTARY DNA; GENE THERAPY AGENT; GLUTAMATE DECARBOXYLASE; NEURTURIN; PROTEIN RPE65; UNCLASSIFIED DRUG;

BLINDNESS; CLINICAL TRIAL; DOPAMINERGIC ACTIVITY; EDITORIAL; GENE MUTATION; GENE THERAPY; HUMAN; INFORMED CONSENT; LEBER CONGENITAL AMAUROSIS; MEDICAL ETHICS; MOLECULAR MECHANICS; PARKINSON DISEASE; PHOTORECEPTOR; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SEVERE COMBINED IMMUNODEFICIENCY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VISUAL ACUITY;

EID: 54949106633     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.218     Document Type: Editorial

References (13)

1. Williams, DA (2008). Progress reported in two studies of clinical gene transfer into the retina. Mol Ther 16: 1181.
2. Maguire, AM, Simonelli, F, Pierce, EA, Pugh, EN Jr, Mingozzi, F., Bennicelli, J et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248.
3. Bainbridge, JW, Smith, AJ, Barker, SS, Robbie, S. Henderson, R. Balaggan, K et al. (2008). Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358: 2231-2239.
4. Hauswirth, W, Aleman, TS, Kaushal, S, Cideciyan, AV, Schwartz, SB, Wang, L et al. (2008). Phase I trial of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-term results. Hum Gene Ther, published online 7 September 2008 .
5. Kaplitt, MG, Feigin, A, Tang, C, Fitzsimons, HL, Mattis, P, Lawlor, PA et al. (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial. Lancet 369: 2097-2105.
6. Feigin, A, Kaplitt, MG, Tang, C, Lin, T, Mattis, P, Dhawan, V et al. (2007). Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci USA 104: 19559-19564.
7. Eberling, JL, Jagust, WJ, Christine, CW, Starr, P, Larson, P, Bankiewicz, KS et al. (2008). Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70: 1980-1983.
8. Marks, WJ Jr, Ostrem, JL, Verhagen, L, Starr, PA, Larson, PS, Bakay, RA et al. (2008). Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: An open-label, phase I trial. Lancet Neurol 7:400-408.
9. Kimmelman, J (2007). Stable ethics: Enrolling non-treatment-refractory volunteers in novel gene transfer trials. Mol Ther 15: 1904-1906.
10. Caplan, AL (2008). If it's broken, shouldn't it be fixed? Informed consent and initial clinical trials of gene therapy. Hum Gene Ther 19: 5-6.
11. Kahn, J (2008). Informed consent in human gene transfer clinical trials. Hum Gene Ther 19: 7-8.
12. Pattee, SR (2008). Protections for participants in gene therapy trials: a patient's perspective. Hum Gene Ther 19: 9-10.
13. Silber, TJ (2008). Human gene therapy, consent, and the realities of clinical research: Is it time for a research subject advocate? Hum Gene Ther 19: 11-14.